A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

Trial Profile

A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Cerliponase alfa (Primary)
  • Indications Neuronal ceroid lipofuscinosis
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 21 Jul 2017 Status changed from recruiting to completed.
    • 06 Sep 2016 According to a BioMarin Pharmaceutical media release, the compassionate use program initially is being conducted at centers that have participated in the cerliponase alfa study and the company continues to work on opening the other sites, while adhering to specific legal and regulatory procedures for each country.
    • 06 Sep 2016 Status changed from planning to recruiting, according to a BioMarin Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top